Natera (NASDAQ:NTRA) Stock: Insider Solomon Moshkevich Sells 3,419 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,419 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $409.77, for a total transaction of $1,401,003.63. Following the completion of the transaction, the insider directly owned 101,323 shares of the company’s stock, valued at approximately $41,519,125.71. The trade was a 3.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, October 28th, Solomon Moshkevich sold 1,162 shares of Natera stock. The shares were sold at an average price of $426.34, for a total transaction of $495,407.08.
• On Tuesday, October 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The stock was sold at an average price of $406.00, for a total transaction of $410,060.00.
• On Thursday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $414.22, for a total transaction of $1,242,660.00.
• On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The shares were sold at an average price of $326.89, for a total transaction of $4,955,652.40.
• On Tuesday, September 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $320.73, for a total transaction of $962,190.00.

Natera Stock Down 7.0%

Natera stock opened at $363.76 on Friday. Natera, Inc. has a twelve month low of $181.00 and a twelve month high of $437.41. The stock’s fifty day simple moving average is $380.81 and its 200-day simple moving average is $269.30.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, November 5th. The medical research company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company had revenue of $793.98 million during the quarter, compared to analysts’ expectations of $707.54 million. During the same quarter last year, the business posted ($0.64) earnings per share. The company’s revenue for the quarter was up 34.1% on a year-over-year basis. On average, analysts predict that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Morgan Stanley boosted their price objective on Natera from $355.00 to $435.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Barclays raised their target price on shares of Natera from $340.00 to $475.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. JPMorgan Chase & Co. lifted their price target on shares of Natera from $360.00 to $460.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. Leerink Partners set a $330.00 price target on shares of Natera in a report on Friday, August 7th. Finally, Zacks Research downgraded shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Friday, October 16th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $394.31.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in shares of Natera during the 2nd quarter worth about $2,962,770,000. K.J. Harrison & Partners Inc purchased a new stake in Natera during the second quarter worth approximately $5,117,000. Abbot Financial Management Inc. acquired a new position in Natera in the second quarter valued at approximately $1,537,000. Eagle Health Investments LP acquired a new position in Natera in the second quarter valued at approximately $4,302,000. Finally, BlueCrest Capital Management Ltd purchased a new position in Natera in the second quarter valued at approximately $11,695,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Third-quarter revenue rose 34.1% year over year to $794.0 million, exceeding analyst expectations of about $707.5 million. The result points to continued business growth. Natera third-quarter 2026 results
• Positive Sentiment: Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could improve access to the test and support adoption of Natera’s oncology products. Medicare coverage for Signatera in HCC
• Neutral Sentiment: Gross margin was 64.7%, nearly unchanged from 64.9% a year earlier, indicating that strong sales growth came with broadly stable margin performance. Natera third-quarter 2026 results
• Neutral Sentiment: Several executives and insiders sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales may attract attention, but their stated purpose and scheduled nature make them less informative about management’s outlook. Natera insider transaction
• Negative Sentiment: Natera reported a quarterly loss of $0.42 per share, wider than analysts’ expected loss of $0.28. The earnings miss likely outweighed the revenue beat and added pressure on the stock. Natera third-quarter 2026 results

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.